Caribou Biosciences (CRBU) Operating Leases (2022 - 2026)
Caribou Biosciences (CRBU) posted quarterly Operating Leases of $25.7 million for Q1 2026, up 5.49% year-over-year from $24.3 million in Q1 2025, and down 1.41% quarter-over-quarter from $26.0 million in Q4 2025.
Caribou Biosciences (CRBU) Operating Leases (2022 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Operating Leases for 5 consecutive years, with $25.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 5.49% year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at $25.7 million (up 5.49% YoY), while the FY2025 annual figure was $26.0 million, up 3.85% from the prior year.
- Operating Leases declined to $25.7 million in Q1 2026 per CRBU's latest filing, from $26.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $27.5 million in Q3 2023 and bottomed at $22.8 million in Q3 2025.
- Historically, Operating Leases has averaged $26.0 million across 5 years, with a median of $26.2 million in 2023.
- Annual changes were most pronounced in 2025 — Operating Leases declined 14.5% — and 2026, when it advanced 5.49%.
- Caribou Biosciences' Operating Leases stood at $26.8 million in 2022, then declined by 3.26% to $25.9 million in 2023, then declined by 3.27% to $25.1 million in 2024, then gained by 3.85% to $26.0 million in 2025, then dropped by 1.41% to $25.7 million in 2026.
- Business Quant data shows CRBU's Operating Leases at $25.7 million in Q1 2026, $26.0 million in Q4 2025, and $22.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - |
| 10 | Caribou Biosciences | 164.10 Mn | 51.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.28 Mn |
| Mar 31, 2026 | 25.66 Mn |
| Dec 31, 2025 | 26.03 Mn |
| Sep 30, 2025 | 22.78 Mn |
| Jun 30, 2025 | 23.56 Mn |
| Mar 31, 2025 | 24.32 Mn |
| Dec 31, 2024 | 25.06 Mn |
| Sep 30, 2024 | 26.64 Mn |
| Jun 30, 2024 | 26.79 Mn |
| Mar 31, 2024 | 25.90 Mn |
| Dec 31, 2023 | 25.91 Mn |
| Sep 30, 2023 | 27.46 Mn |
| Jun 30, 2023 | 26.16 Mn |
| Mar 31, 2023 | 27.42 Mn |
| Dec 31, 2022 | 26.78 Mn |
| Sep 30, 2022 | 26.96 Mn |
| Jun 30, 2022 | 27.09 Mn |
| Mar 31, 2022 | 27.24 Mn |